Actively Recruiting
Observational Study Evaluating Anti-IL1 Therapies Anakinra and Canakinumab in Severe Fibrodysplasia Ossificans Progressiva FOP Patients Aged 6 to 30
Led by University of California, San Francisco · Updated on 2026-08-06
11
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an observational study to examine if off-label anti-IL1 therapies, such as anakinra or canakinumab, can reduce flare activity and heterotopic bone formation in patients with severe Fibrodysplasia Ossificans Progressiva FOP caused by the ACVR1 mutation. This study aims to collect important preliminary data and tools needed for future Phase II trials, focusing on patients experiencing unusually severe or intractable flare-ups. The study includes patients aged 6 to 30 who have decided with their medical team to start anti-IL1 therapy due to severe disease progression. Participants will be observed during the medication approval process and followed for up to one year after treatment initiation. Assessments include low-dose whole-body CT scans, blood tests, patient-reported outcomes on pain and flare activity, and mobility evaluations. Separate observational arms include patients already on anti-IL1 therapy or those unable to access it, to collect historical data. Participants will undergo regular assessments of flare frequency, new bone growth, inflammatory markers, and mobility changes over one year. Safety is monitored by recording any treatment-related adverse events. The study involves blood draws, imaging, and questionnaires, and participants must be able to travel for visits. Overall participation spans from pre-treatment observation through one year of follow-up after starting therapy.
CONDITIONS
Brief Title
IL1 Inhibition in FOP
Research Team
S
Samantha Klein
J
Judy Gonzalez-Vargas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here